

PE/Cyanine7 anti-mouse CD45 Antibody

Catalog# / Size	103113 / 25 µg 103114 / 100 µg
Clone	30-F11
Regulatory Status	RUO
Other Names	T200, Ly-5, LCA
Isotype	Rat IgG2b, κ
Description	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse thymus or spleen
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45. Additional reported applications (for relevant formats) include: immunoprecipitation ³ , complement-dependent cytotoxicity ^{1,5} , immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections) ^{4,6} , Western blotting ⁷ , and spatial biology (IBEX) ^{10,11} . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).
Additional Product Notes	BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References	<ol style="list-style-type: none"> 1. Podd BS, <i>et al.</i> 2006. <i>J. Immunol.</i> 176:6532. (FC, CMCD) PubMed 2. Haynes NM, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:5099. (FC) 3. Ledbetter JA, <i>et al.</i> 1979. <i>Immunol. Rev.</i> 47:63. (IP) 4. Simon DI, <i>et al.</i> 2000. <i>J. Clin. Invest.</i> 105:293. (IHC)

5. Seaman WE. 1983. *J. Immunol.* 130:1713. (CMCD)
6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)
8. Liu F, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Khare A, *et al.* 2016. *Cell Rep.* 15: 1700-1714. [PubMed](#)
2. Bussi eres-Marmen S, *et al.* 2017. *Cell Mol Immunol.* 10.1038/cmi.2016.72. [PubMed](#)
3. Tran NT, *et al.* 2019. *Cell Rep.* 28:3510. [PubMed](#)
4. Garber C, *et al.* 2019. *Nat Neurosci.* 1.802777778. [PubMed](#)
5. Dobie R, *et al.* 2020. *Cell Reports.* 29(7):1832-1847.e8.. [PubMed](#)
6. Wu JH, *et al.* 2020. *EMBO Mol Med.* 12:e10154. [PubMed](#)
7. Rodriguez de la Fuente L, *et al.* 2021. *STAR Protoc.* 2:100841. [PubMed](#)
8. Yokozeki Y, *et al.* 2021. *Biomed Res Int.* 2021:7988320. [PubMed](#)
9. Sch adlich IS, *et al.* 2022. *iScience.* 25:104470. [PubMed](#)
10. Yang AC, *et al.* 2020. *Nature.* 583:425. [PubMed](#)
11. Tan L, *et al.* 2022. *Aging Dis.* 13:1562. [PubMed](#)
12. Yagishita Y, *et al.* 2020. *Cell Mol Gastroenterol Hepatol.* . [PubMed](#)
13. Wiesner DL, *et al.* 2020. *Cell Host Microbe.* 614:27. [PubMed](#)
14. Wagner G, *et al.* 2017. *Sci Rep.* 7:40881. [PubMed](#)
15. Weeden C, *et al.* 2017. *PLoS Biol.* 10.1371/journal.pbio.2000731. [PubMed](#)
16. Hilliard K, *et al.* 2015. *Infect Immun.* 83: 4015 - 4027. [PubMed](#)
17. Shi Y, *et al.* 2020. *Med Sci Monit.* 26:e923328. [PubMed](#)
18. Smith NR, *et al.* 2017. *Cell Mol Gastroenterol Hepatol.* 0.395138889. [PubMed](#)
19. Zhou J, *et al.* 2019. *Immunity.* 50:403. [PubMed](#)
20. Abels ER *et al.* 2019. *Cell Rep.* 28(12):3105-3119 . [PubMed](#)
21. Chang T, *et al.* 2017. *PLoS Pathog.* 10.1371/journal.ppat.1006485. [PubMed](#)
22. Garcia-Prat L, *et al.* 2020. *Nat Cell Biol.* 22:1307. [PubMed](#)
23. Tatsuguchi T, *et al.* 2022. *Int Immunol.* 34:277. [PubMed](#)
24. Pan J, *et al.* 2021. *Mol Ther Nucleic Acids.* 26:970. [PubMed](#)
25. Helms EJ, *et al.* 2021. *Cancer Discov.* Online ahead of print. [PubMed](#)
26. Huck NA, *et al.* 2021. *J Neurosci.* 41:4349. [PubMed](#)
27. Wu Q, *et al.* 2021. *Cancer Commun (Lond).* Online ahead of prin. [PubMed](#)
28. Ma Q, *et al.* 2021. *Clin Transl Immunology.* 10:e1300. [PubMed](#)
29. Vila Ellis L, *et al.* 2020. *Dev Cell.* 617:52. [PubMed](#)
30. Wilson RP, *et al.* 2019. *PLoS Pathog.* 15:e1007745. [PubMed](#)
31. Barry KC, *et al.* 2018. *Nat Med.* 24:1178. [PubMed](#)
32. Saleh MM, *et al.* 2019. *Cell Host Microbe.* 25:756. [PubMed](#)
33. Mansouri N, *et al.* 2019. *JCI Insight.* 4:e128060. [PubMed](#)
34. Kim YS, *et al.* 2021. *Cell Death Dis.* 12:307. [PubMed](#)
35. Song J, *et al.* 2021. *J Am Heart Assoc.* 10:e017329. [PubMed](#)
36. Manivasagam S, *et al.* 2022. *J Immunol.* 208:1341. [PubMed](#)
37. Bauer KM, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
38. Fu Y, *et al.* 2020. *Mol Ther.* 1214:28. [PubMed](#)
39. Han Y, *et al.* 2020. *Nat Commun.* 11:1776. [PubMed](#)
40. White MPJ, *et al.* 2020. *Front Immunol.* 11:1830. [PubMed](#)
41. Saito S, *et al.* 2020. *Nutrients.* 12:. [PubMed](#)
42. Mathews J, *et al.* 2014. *PLoS One.* 9:97707. [PubMed](#)
43. Britschgi A, *et al.* 2017. *Nature.* 541:541-545. [PubMed](#)
44. Valds-Mora F, *et al.* 2021. *Cell Reports.* 35(2):108945. [PubMed](#)
45. DellOrso S, *et al.* 2021. *STAR Protocols.* 2(2):100451. [PubMed](#)
46. Wang B, *et al.* 2017. *EBioMedicine.* 10.1016/j.ebiom.2017.03.041. [PubMed](#)
47. Kaczmarek-H ajek K, *et al.* 2018. *Elife.* 7:e36217. [PubMed](#)
48. Nakagawa S *et al.* 2017. *Cell host & microbe.* 22(5):667-677 . [PubMed](#)
49. Ohigashi I, *et al.* 2020. *Cell Reports.* 29(9):2901-2916.e6.. [PubMed](#)
50. Zhong J, *et al.* 2018. *Sci Adv.* 4:eaas9864. [PubMed](#)
51. Kobayashi H, *et al.* 2020. *STAR Protoc.* 1:100078. [PubMed](#)
52. Little DR, *et al.* 2021. *Nat Commun.* 12:2509. [PubMed](#)
53. Bhopale VM, *et al.* 2021. *J Appl Physiol (1985).* 130:1604. [PubMed](#)
54. Zheng L, *et al.* 2022. *J Neuroinflammation.* 19:128. [PubMed](#)
55. Jiang YH, *et al.* 2020. *J Mol Cell Cardiol.* 138:115. [PubMed](#)
56. Pan J, *et al.* 2020. *J Neuroinflammation.* 17:97. [PubMed](#)
57. Best SA, *et al.* 2018. *Cell Metab.* 27:935. [PubMed](#)
58. Garber C, *et al.* 2018. *Nat Immunol.* 19:151. [PubMed](#)
59. Campanario S, *et al.* 2021. *Front Cell Dev Biol.* 8:620409. [PubMed](#)
60. Cousin N, *et al.* 2021. *Cancer Res.* 81:4133. [PubMed](#)
61. Mizuochi C, *et al.* 2012. *PLoS One.* 7:e35763. [PubMed](#)
62. Gigliotti J, *et al.* 2013. *J Am Soc Nephrol.* 24:1451. [PubMed](#)
63. Wang B, *et al.* 2017. *Cell Discov.* 10.1038/celldisc.2017.36. [PubMed](#)
64. Solanas G, *et al.* 2017. *Cell.* 170:678. [PubMed](#)
65. Dubey LK, *et al.* 2019. *Cell Rep.* 27:2442. [PubMed](#)
66. Chen C, *et al.* 2019. *Cell Rep.* 29:4200. [PubMed](#)
67. Galv o I, *et al.* 2018. *Front Immunol.* 9:142. [PubMed](#)
68. Bahar Halpern K, *et al.* 2020. *Nat Commun.* 11:1936. [PubMed](#)
69. Hurrell BP, *et al.* 2019. *Cell Rep.* 29:4509. [PubMed](#)
70. Gu H, *et al.* 2018. *Aging (Albany NY).* 1.525694444. [PubMed](#)

71. McGowan SE, *et al.* 2018. Am J Physiol Lung Cell Mol Physiol. 315:L102. [PubMed](#)
72. Cheng HW, *et al.* 2019. Nat Commun. 10:1739. [PubMed](#)
73. Cong J *et al.* 2018. Cell metabolism. 28(2):243-255 . [PubMed](#)
74. Yang R, *et al.* 2022. Front Pharmacol. 13:774440. [PubMed](#)
75. Fix DK, *et al.* 2021. Aging Cell. 20:e13448. [PubMed](#)
76. Cassidy BR, *et al.* 2020. J Neuroinflammation. 17:259. [PubMed](#)
77. Zhu L, *et al.* 2021. Stem Cell Res Ther. 12:408. [PubMed](#)
78. Allen S, *et al.* 2011. J Virol. 85:11448. [PubMed](#)
79. Jaworska K, *et al.* 2015. J Immunol. 194:325. [PubMed](#)
80. Furuya Y, *et al.* 2015. PLoS Pathog. 11: 1005180. [PubMed](#)
81. Gomzikova MO, *et al.* 2020. Sci Rep. 10:10740. [PubMed](#)
82. Cain MP, *et al.* 2020. Dis Model Mech. 13:00. [PubMed](#)
83. Court AC, *et al.* 2020. EMBO Rep. 21:e48052. [PubMed](#)
84. Okubo K, *et al.* 2021. Cell Reports. 35(7):109142. [PubMed](#)
85. Onder L *et al.* 2017. Immunity. 47(1):80-92 . [PubMed](#)
86. Halpern KB, *et al.* 2018. Nat Biotechnol. 36:962. [PubMed](#)
87. Kimbrough D, *et al.* 2018. J Mol Cell Cardiol. 119:51. [PubMed](#)
88. Codina A, *et al.* 2019. Cell Syst. 8:136. [PubMed](#)
89. Srivastava S, *et al.* 2019. Cancer Cell. 35:489. [PubMed](#)
90. Wang W, *et al.* 2020. Immunity. 51(6):1102-1118.e7.. [PubMed](#)
91. Huang CH, *et al.* 2020. Adv Ther (Weinh). 3:. [PubMed](#)
92. Mao FY, *et al.* 2021. Cell Mol Gastroenterol Hepatol. 12:395. [PubMed](#)
93. Okamura T, *et al.* 2021. Front Immunol. 12:669629. [PubMed](#)
94. Dang Y, *et al.* 2021. J Cancer. 12:7158. [PubMed](#)
95. Basu A, *et al.* 2021. Cancer Immunol Res. Online ahead of print. [PubMed](#)
96. Fennell LM, *et al.* 2020. EMBO J. 39:e103303. [PubMed](#)
97. Zhu H, *et al.* 2021. Cell Metabolism. .: [PubMed](#)
98. McCoy S 2015. Am J Physiol Lung Cell Mol Physiol. 309: L463-L474. [PubMed](#)
99. Yen Y, *et al.* 2008. J Virol. 82:12312. [PubMed](#)
100. Uribesalgo I, *et al.* 2019. EMBO Mol Med. 11:e9266. [PubMed](#)
101. Son NH, *et al.* 2018. J Clin Invest. 128:4329. [PubMed](#)
102. Ellegast JM, *et al.* 2022. Cancer Discov. 12:1760. [PubMed](#)
103. Liu T, *et al.* 2022. Front Immunol. 13:901349. [PubMed](#)
104. Goldfarb Y, *et al.* 2021. J Exp Med. 218:. [PubMed](#)
105. Manco R, *et al.* 2021. Nat Commun. 12:3074. [PubMed](#)
106. Zuo W, *et al.* 2022. Cell Death Discov. 8:257. [PubMed](#)
107. Berg AL, *et al.* 2022. Cancers (Basel). 14:. [PubMed](#)
108. Ishii H, *et al.* 2012. Cell Death Dis. 9;3:e363. [PubMed](#)
109. Wang F, *et al.* 2021. Cell. 184(2):422-440.e17. [PubMed](#)
110. Deerkake ME, *et al.* 2021. Immunity. 54(3):484-498.e8. [PubMed](#)
111. Kellish P, *et al.* 2019. J Clin Invest. 130:2279. [PubMed](#)
112. Magri G *et al.* 2017. Immunity. 47(1):118-134 . [PubMed](#)
113. Sela Y, *et al.* 2021. Elife. 10: . [PubMed](#)
114. Galle-Treger L, *et al.* 2016. Nat Commun. 7:13202. [PubMed](#)
115. Sydney Lavoie *et al.* 2019. eLife. 8 pii: e39982. [PubMed](#)
116. Pascual G, *et al.* 2021. Nature. 599:485. [PubMed](#)
117. Kolodziejczyk AA, *et al.* 2020. Nat Med. 26:1899. [PubMed](#)
118. Galle-Treger L, *et al.* 2020. J Allergy Clin Immunol. 145:502. [PubMed](#)
119. Chu X, *et al.* 2021. Front Cell Dev Biol. 9:671841. [PubMed](#)
120. Shafiei-Jahani P, *et al.* 2021. Nat Commun. 12:2526. [PubMed](#)
121. Wu X, *et al.* 2016. Sci Rep. 6:18685. [PubMed](#)
122. Hasegawa T, *et al.* 2020. Sci Rep. 10:13480. [PubMed](#)
123. Evgin L, *et al.* 2020. Nat Commun. 2.671527778. [PubMed](#)
124. van Gastel N, *et al.* 2020. Cell Metabolism. 32(3):391-403.e6. [PubMed](#)
125. Gubin MM, *et al.* 2018. Cell. 175:1014. [PubMed](#)
126. Galle-Treger L, *et al.* 2019. Nat Commun. 10:713. [PubMed](#)
127. Kobayashi H, *et al.* 2020. Cell Reports. 28(1):145-158.e9.. [PubMed](#)
128. Merrell AJ, *et al.* 2021. Hepatology. 74:444. [PubMed](#)
129. Jin L, *et al.* 2022. J Immunol Res. 2022:7222638. [PubMed](#)
130. Koyama T, *et al.* 2022. Curr Issues Mol Biol. 44:3146. [PubMed](#)
131. Evgin L, *et al.* 2022. Sci Transl Med. 14:eabn2231. [PubMed](#)
132. Nenasheva T, *et al.* 2017. PLoS One. 12(6):e0178983. [PubMed](#)
133. Shen DD, *et al.* 2022. Mol Cancer. 21:75. [PubMed](#)
134. Zhu J, *et al.* 2021. Cancer Cell Int. 21:529. [PubMed](#)
135. Yuan M, *et al.* 2022. Oxid Med Cell Longev. 2022:5479491. [PubMed](#)
136. Abdelfattah N, *et al.* 2022. Nat Commun. 13:767. [PubMed](#)
137. Li J, *et al.* 2020. Development. . [PubMed](#)
138. Tang Z, *et al.* 2021. Stem Cell Res Ther. 12:397. [PubMed](#)
139. Ben-Yehuda H, *et al.* 2021. Mol Neurodegener. 16:39. [PubMed](#)
140. Magness S, *et al.* 2013. Am J Physiol Gastrointest Liver Physiol. 305:542. [PubMed](#)
141. Wang W, *et al.* 2021. STAR Protocols. 2(3):100756. [PubMed](#)
142. Li S, *et al.* 2019. Front Neurol. 1.036805556. [PubMed](#)
143. Liu YG, *et al.* 2019. FASEB J. 33:5018. [PubMed](#)
144. Mohammadpour H, *et al.* 2021. Cell Rep. 37:109883. [PubMed](#)
145. Zhu S, *et al.* 2022. EBioMedicine. 80:104060. [PubMed](#)
146. Sung PS, *et al.* 2022. JCI Insight. .: [PubMed](#)
147. Zhang J, *et al.* 2022. Biomater Res. 26:44. [PubMed](#)
148. Namkoong H, *et al.* 2018. PLoS Pathog. 14:e1006955. [PubMed](#)
149. Clemente-Casares X, *et al.* 2017. Immunity. 47:974. [PubMed](#)
150. Smith NR, *et al.* 2018. Cell Mol Gastroenterol Hepatol. 6:79. [PubMed](#)

151. Zhu K, *et al.* 2022. EMBO Rep. 23:e54499. [PubMed](#)
152. Nian Z, *et al.* 2021. Clin Cancer Res. 27:6026. [PubMed](#)
153. Leary N, *et al.* 2022. J Extracell Vesicles. 11:e12197. [PubMed](#)
154. Hakim R, *et al.* 2021. J Neurosci. 41:8441. [PubMed](#)
155. Ogrjenovic NB, *et al.* 2020. Dev Cell. 55:544. [PubMed](#)
156. Gu H, *et al.* 2021. Elife. 10:. [PubMed](#)
157. Hendee K, *et al.* 2021. Aging (Albany NY). 13:7781. [PubMed](#)
158. Issah Y, *et al.* 2021. Elife. 10:. [PubMed](#)
159. Hering L, *et al.* 2020. Front Immunol. 1.747222222. [PubMed](#)
160. Di Pilato M, *et al.* 2021. Cell. 184(17):4512-4530.e22. [PubMed](#)
161. Béchade C, *et al.* 2020. Glia. . [PubMed](#)
162. Yoshida H, *et al.* 2019. Cell. 176:897. [PubMed](#)
163. Kelley WJ, *et al.* 2022. JCI Insight. .: [PubMed](#)
164. Rai S, *et al.* 2022. Nat Commun. 13:5346. [PubMed](#)
165. Fan X, *et al.* 2020. Acta Physiol (Oxf). 230:e13475. [PubMed](#)
166. Fang Y, *et al.* 2022. Development. 149:. [PubMed](#)
167. Gong P, *et al.* 2022. Cell Death Discov. 8:466. [PubMed](#)
168. Sheng J, *et al.* 2021. eLife. 10:00. [PubMed](#)
169. Moreno M *et al.* 2014. The Journal of Neuroscience. 34(24):8175-85. [PubMed](#)
170. Nguyen HX *et al.* 2017. J Neurosci. 37(38):9269-9287. [PubMed](#)
171. Ishihara J, *et al.* 2018. Nat Commun. 9:2163. [PubMed](#)
172. Oh J, *et al.* 2021. Clin Cancer Res. 27:4781. [PubMed](#)
173. Li Q, *et al.* 2022. J Biol Chem. :101753. [PubMed](#)
174. Dong H, *et al.* 2022. Nat Metab. 4:90. [PubMed](#)
175. Andreou T, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
176. Rochford I, *et al.* 2021. Am J Physiol Lung Cell Mol Physiol. 321:L686. [PubMed](#)
177. Hussein M, *et al.* 2015. PLoS One. 10: 0135218. [PubMed](#)
178. Gigliotti J, *et al.* 2015. J Am Soc Nephrol. 26: 2470 - 2481. [PubMed](#)
179. Serr I, *et al.* 2016. Nat Commun. 7:10991. [PubMed](#)
180. Gerner-Mauro KN, *et al.* 2020. Proc Natl Acad Sci U S A. 117:12182. [PubMed](#)
181. Kimmel JC, *et al.* 2021. Cell Reports. 35(4):109046. [PubMed](#)
182. Tian T, *et al.* 2020. Cancer Immunol Res. 660:8. [PubMed](#)
183. Ghosh S, *et al.* 2019. Commun Biol. 0.325. [PubMed](#)
184. Dourcy M, *et al.* 2020. Mucosal Immunol. 13:799. [PubMed](#)
185. Spiljar M, *et al.* 2021. Cell Metab. 33:2231. [PubMed](#)
186. Wu H, *et al.* 2020. Cell. 180(1):107-121.e17.. [PubMed](#)
187. Muri J, *et al.* 2020. Cell Reports. 30(13):4399-4417. [PubMed](#)
188. Chithanathan K, *et al.* 2022. Biology (Basel). 11:. [PubMed](#)
189. Aggarwal N, *et al.* 2021. Cell Rep. 37:110170. [PubMed](#)
190. Zhong J, *et al.* 2021. Commun Biol. 4:865. [PubMed](#)
191. Song X, *et al.* 2021. FEBS Open Bio. 11:2453. [PubMed](#)
192. Ren X, *et al.* 2021. Cell Death Dis. 12:484. [PubMed](#)

RRID AB_312978 (BioLegend Cat. No. 103113)
 AB_312979 (BioLegend Cat. No. 103114)

Antigen Details


Structure	Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution	All hematopoietic cells except mature erythrocytes and platelets
Function	Phosphatase, T and B cell activation
Ligand/Receptor	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85. 3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143. 4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.
Gene ID	19264

Related Protocols

Other Formats

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

Product Data



C57BL/6 mouse splenocytes stained with 30-F11 PE/Cyanine7

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587